Methods for diagnosing an increased risk for breast or ovarian c

Details Methods for diagnosing an increased risk for breast or ovarian c Methods for diagnosing an increased risk for breast or ovarian c

1996-12-03

1997-11-04

Jones, W. Gary

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

5303871, 5303877, G01N 3353, C07K 1600, C12P 2108

Patent

active

056838859

ABSTRACT:
The present invention relates to method for diagnosing an increased risk for breast or ovarian cancer by assaying for the presence of a mutant human progesterone receptor protein which contains a valine to leucine substitution at amino acid 660, wherein the presence of said mutant human progesterone receptor protein indicates an increased risk for breast or ovarian cancer.

REFERENCES:
patent: 4742000 (1988-05-01), Greene
patent: 5283190 (1994-02-01), Traish et al.
patent: 5364791 (1994-11-01), Vegeto et al.
Kieback et al., "Die Chemische Heteroduplexspaltung-- Ein Verfahren Zur Entdeckung von Mutationen in Ostrogen-und Progesteronrezeptorgenen beim Mammakarzinom", Archives of Gynecology and Obstetrics, 250(1-4):249-250 (Sep. 11-15, 1990) (and English Translation).
McKenna et al, "A Germline TagI Restriction Fragment Length Polymorphism in the Progesterone Receptor Gene in Ovarian Carcinoma", British J. of Cancer, 71:451-455 (1995).
Rodriguez et al, "Dimerization of the Chicken Progesterone Receptor In Vitro Can Occur in the Absence of Hormone and DNA", Molecular Endocrinology, 4(11):1782-1790 (1990).
Allan et al, "Ligand-Dependent Conformational Changes in the Progesterone Receptor are Necessary for Events that follow DNA Binding", Proc. Natl. Acad. Sci., USA 89:11750-11754 (1992).
Allan et al, "Hormorne and Antihormone Induce Distinct Conformational Changes Which are Central to Steroid Receptor Activation", J. Biol. Chem., 267(27):19513-19520 (1992).
Sheridan et al, "Synthesis of Human Progesterone Receptors in T47D Cells", J. Biol. Chem., 264(12):7054-7058 (1989).
Tsai et al, "Molecular Mechanisms of Action of Steroid/Thyroid Receptor Superfamily Members", Ann. Rev. Biochem., 63:451-486 (1994).
Zhang et al, "Multiple Signaling Pathways Activate the Chicken Progesterone Receptor", Mol. Endo., 8(5):577-584 (1994).
Bai et al, "Phosphorylation of Ser.sup.530 Facilitates Hormone-Dependent Transcriptional Activation of the Chicken Progesterone Receptor", Mol. Endo., 80(11):1465-1473 (1994).
Agoulnik et al, "Genetic Mutation in the Human Progesterone Receptor Gene Associated with Increased Cancer Risk Lead to a Structurally and Functionally Altered Receptor Protein", Proceedings, 87th Annual Meeting of the American Association Cancer Research, Washington, D.C., vol. 37, Abstract No. 1514 (Apr. 20-24, 1996).
Garrett et al, "Mendelian Inheritance of a TagI Restriction Fragment Length Polymorphism Due to an Insertion in the Human PR Gene and Its Allelic Imbalance in Breast Cancer", Cancer Res., Therapy and Control, pp. 1-8 (1995).
Allgood et al, "Adaptation of a Novel Adenoviral Expression System to Study Function and Covalent Modification of Avian Progesterone Receptor", 76th Endocrine Society Meeting, Abst. No. 631 (1994).
Tong et al, A TagI RFLP in the Human Progesterone Receptor Gene (HPR) is Associated with Ovarian Cancer, ACR Meeting, 86th Annual Association for Cancer Research, (Preliminary Program), Toronto, Ontario, Canada, Abstract (Mar. 18-22, 1995).
Levy et al, "Chicken Ovalbumin Upstream Promoter--Transcription Factor (COUP-TF-Like) Expression in Human Endometrial Cancer Cell Lines", 42nd Annual Society for Gynecologic Investigation, Chicago, Illinois, Abstract (Mar. 15-18, 1995).
Kieback et al, "A Genetic Mutation in the Human Progesterone Receptor Gene (HPR) is Associated with Ovarian Cancer", Society of Gynecological Oncologist, San Francisco, Calif., Marriott Hotel, 26th Annual Meeting, (Program in Brief), Abstract (Feb. 18-22, 1995).
Kieback et al, "A TagI RFLP in the Human Progesterone Receptor Gene is Associated with Sporadic Epithelial Ovarian Cancer and with Breast Cancer", Society for Gynecologic Investigation, 42nd Annual Scientific Meeting (Postgraduate Courses), Chicago, Illinois, Abstract (Mar. 15-18, 1995).
Rowe et al, "The Ovarian Carcinoma-Associated TagI Restriction Fragment Length Polymorphism in Intron G of the Progesterone Receptor Gene is Due to Alu Sequence Insertion", Cancer Research,55:2743-2745 (1995).
Zhang et al, "Identification of a Group of Ser-Pro Motif Hormone-Inducible Phosphorylation Sites in the Human Progesterone Receptor", Mol. Endo., 9(8):1029-1040 (1995).
Fuqua et al, "Progesterone Receptor Gene Restriction Fragment Length Polymorphisms in Human Breast Tumors", J. Nat'l. Cancer Institute, 83(16):1157-1160 (1991).
Kieback et al, "A Complex of Mutations in the Human Progesterone Receptor Gene in Associated with Increased Risk of Non-familial Breast and Ovarian Cancer but not of Uterine Cancer", Proceedings, 87th Annual Meeting of the American Association Cancer Research, Washington, D.C., vol. 37, Abstract No. 1704 (Apr. 20-24, 1996).
Garrett et al., Cancer Res. Ther. Control, 4:217-222 (1995).
Rowe et al, Cancer Res., 55:2743-2745 (1995).
McKenna et al, British J. Cancer, 71:451-455 (1995).
Kieback et al, Anticancer Res., 15:1766-1767 (1995).
Tong et al, Proc. Annu. Meet. Amer. Assoc. Cancer Res., 36:A3760 (1995).
Miller (1992) Dissertation abstract entitled Variant Forms of Estrogen and Progesterone Receptors in the T47D(CO) Human Breast Cancer Cell Line (Estrogen Receptor, T47D(CO)). Dissertation Abstracts International, vol. 53, No. 6b p. 2795.
Zhao (1993) Dissertation abstract entitled Cloning Expression and Characterization of a Truncated Bovine Progesterone Receptor. Dissertation Abstracts International, vol. 55, No. 2B p. 326.
Leygue et al. (Nov. 1996) Biochem. Biophys. Res. Commun. 228:63-68, abstract.
Wei et al. (Nov. 1996) Mol. Endocrinol. 10:1379-87, abstract.
Xu et al. (Oct. 1996) Proc. Natl. Acad. Sci. USA 93:12195-99.

Affiliated with

Also associated with

Rating

Methods for diagnosing an increased risk for breast or ovarian c does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for diagnosing an increased risk for breast or ovarian c, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for diagnosing an increased risk for breast or ovarian c will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1832271